Biopharmaceutical company developing therapies for rare mineralization disorders.
Inozyme Pharma, Inc. is a pioneering biopharmaceutical firm dedicated to addressing rare diseases characterized by abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. At the forefront of its innovative pipeline is INZ-701, a soluble recombinant protein designed to combat the rare genetic disorders associated with deficiencies in ENPP1 and ABCC6, as well as to potentially treat calciphylaxis, a severe condition involving mineral deposits in blood vessels.
The company has forged a pivotal license agreement with Yale University, focusing on the development of specified therapeutic and prophylactic products aimed at tackling these challenging diseases. Founded in 2015 and headquartered in Boston, Massachusetts, Inozyme Pharma, Inc. leverages cutting-edge scientific research to drive its mission of advancing novel treatments for underserved patient populations.
Inozyme Pharma is committed to pushing the boundaries of medical innovation through rigorous research and development efforts. By concentrating on diseases often overlooked by traditional pharmaceutical research, the company aims to make a profound impact on the lives of patients worldwide. Through strategic partnerships and collaborations, Inozyme Pharma seeks to accelerate the development and accessibility of transformative therapies, reinforcing its dedication to pioneering solutions that address unmet medical needs.
With a strong emphasis on scientific excellence and patient-centric care, Inozyme Pharma continues to expand its portfolio with a focus on rare diseases marked by abnormal mineralization. By harnessing its expertise and strategic collaborations, the company remains steadfast in its pursuit of advancing therapies that not only treat symptoms but also enhance the overall quality of life for individuals affected by these challenging conditions.